# Growth Hormone in a Patient With a Dominant-Negative GHR Mutation

> **NCT05382637** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Children's National Research Institute** · enrollment: 1 (actual)

## Conditions studied

- Growth Disorders

## Interventions

- **DRUG:** Somatropin

## Key facts

- **NCT ID:** NCT05382637
- **Lead sponsor:** Children's National Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-08-26
- **Primary completion:** 2023-09-01
- **Final completion:** 2028-09-01
- **Target enrollment:** 1 (ACTUAL)
- **Last updated:** 2025-07-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05382637

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05382637, "Growth Hormone in a Patient With a Dominant-Negative GHR Mutation". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT05382637. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*